Cancer.com [homepage on the Internet]. National Cancer Institute at the National Institutes of Health; 2011 [cited 18 March 2014]. Available from: „Archived copy”. Arhivirano iz originala na datum 08. 02. 2015.. Pristupljeno 26. 10. 2018.
„Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration”. Canadian Journal of Ophthalmology. Journal Canadien d'Ophtalmologie40 (3): 352–68. 01. 06. 2005.. DOI:10.1016/S0008-4182(05)80078-X. PMID15947805.
„Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer”. The Oncologist12 (4): 443-50. 2007. DOI:10.1634/theoncologist.12-4-443. PMID17470687.
Keith Parker; Laurence Brunton; Goodman, Louis Sanford; Lazo, John S.; Gilman, Alfred (2006). „IV. Miscellaneous agents; Thalidomide”. Goodman & Gilman's The Pharmacological Basis of Therapeutics (11 izd.). New York: McGraw-Hill. ISBN0-07-142280-3.
Blázquez C, González-Feria L, Alvarez L, Haro A, Casanova ML, Guzmán M (August 2004). "Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas". Cancer Research. 64 (16): 5617–23. doi:10.1158/0008-5472.CAN-03-3927. PMID15313899.
ncbi.nlm.nih.gov
„Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration”. Canadian Journal of Ophthalmology. Journal Canadien d'Ophtalmologie40 (3): 352–68. 01. 06. 2005.. DOI:10.1016/S0008-4182(05)80078-X. PMID15947805.
„Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer”. The Oncologist12 (4): 443-50. 2007. DOI:10.1634/theoncologist.12-4-443. PMID17470687.
web.archive.org
Cancer.com [homepage on the Internet]. National Cancer Institute at the National Institutes of Health; 2011 [cited 18 March 2014]. Available from: „Archived copy”. Arhivirano iz originala na datum 08. 02. 2015.. Pristupljeno 26. 10. 2018.
